These benefits, together with a preceding report showing that a little-molecule ACKR3 agonist CCX771 reveals anxiolytic-like behavior in mice,two assist the thought of targeting ACKR3 as a novel technique to modulate the opioid program, which could open new therapeutic avenues for opioid-related